格隆汇12月22日｜格隆汇今日线上举办"科技赋能·资本破局"分享会。备受瞩目的卓越公司评选榜单隆 重揭晓。其中，格隆汇"金格奖"年度卓越公司评选中，美丽田园医疗健康(2373.HK)荣获"年度品牌价值 奖"奖项。 "年度品牌价值奖"旨在表彰资本市场中拥有最高品牌价值的企业。品牌作为企业生存和发展的核心，做 好一个品牌，对于每个企业来说都是重中之重。本奖项从品牌差异化、知名度、客户忠诚度等多角度衡 量品牌价值，甄选出的企业都创造了卓越品牌，并在品牌价值提升的过程中做出创新和不凡实践。 ...

Core Insights - The "Golden Award" annual outstanding company selection by Gelonghui will reveal a list of notable companies, including Aneng Logistics, BYD, Oriental Yuhong, and others, recognized for their brand value in the capital market [1] - The "Annual Brand Value Award (Large Market Capitalization)" aims to honor companies with the highest brand value, emphasizing the importance of brand differentiation, recognition, and customer loyalty [1][2] Group 1: Award Recipients - Ten companies received the "Annual Brand Value Award (Large Market Capitalization)" including Aneng Logistics (09956.HK), BYD (002594.SZ/01211.HK), and Lenovo Group (00992.HK) [1] - The award selection process involved quantitative data analysis and expert review to determine the final results [1] Group 2: Evaluation Criteria - The evaluation of brand value considered multiple factors such as brand differentiation, recognition, and customer loyalty [1] - The aim of the award is to create a reference for the most valuable listed companies and unicorns in the investment community [2]

Core Viewpoint - The report from First Shanghai highlights that Meili Tianyuan Medical Health (02373) is enhancing its operational and integration capabilities through a dual approach of "internal growth + external expansion," with a target price of HKD 43.7 and an initial buy rating [1]. Group 1: Business Model and Ecosystem - Meili Tianyuan has established a "Double Beauty + Double Health" collaborative business model, creating a comprehensive beauty and health ecosystem that includes brands like Meili Tianyuan, Nairui'er, Xiuker, and Yanyuan, covering a full lifecycle of services from high-end beauty to health management [2]. - The core services focus on "lifestyle beauty + medical beauty + sub-health management," guiding customers from lifestyle beauty to high-value medical and health services, thus achieving comprehensive lifecycle management [2]. Group 2: Growth Strategy - The company employs a dual strategy of "internal growth + external expansion" to enhance operational and integration capabilities, utilizing 38 self-developed systems for refined operations, maintaining a customer repurchase rate above 80%, and keeping customer acquisition costs below 2% [3]. - On the external front, the company has made strategic acquisitions of Nairui'er and Siyanli, leveraging strong cash flow to significantly increase membership scale and net profit margins, showcasing strong synergy and integration capabilities [3]. Group 3: Industry Trends - Meili Tianyuan is positioned to lead the transformation of the beauty industry, which is trending towards branding, chain operations, and digitalization, by leveraging its multi-brand strategy, nationwide store network, and advanced digital systems [4]. - The company aims to transition the industry from a fragmented state to a more consolidated and robust structure, enhancing customer value through its "Double Beauty + Double Health" ecosystem [4]. Group 4: Financial Performance - In the first half of 2025, the company reported strong performance with direct store traffic reaching 920,000, a year-on-year increase of 47.8%, and active members rising to 120,000, up 46.5% [5]. - Revenue reached RMB 1,459 million, reflecting a year-on-year growth of 28.2%, while adjusted net profit was RMB 191 million, achieving a record high adjusted net profit margin of 13.1%, demonstrating exceptional profitability resilience amid macro pressures [5]. Group 5: Profit Forecast - The company has significant growth potential driven by both internal growth and acquisition capabilities, with its true growth boundary dependent on management capabilities [6]. - Using a discount rate of 10% and a perpetual growth rate of 3%, the estimated fair value of the company is HKD 10.3 billion, with a target price of HKD 43.7, indicating a potential upside of 65.4% from the previous closing price, corresponding to PE ratios of 29.8 and 24.5 for 2025 and 2026 respectively, thus receiving a buy rating [6].

Core Viewpoint - First Shanghai initiates coverage of Meili Tianyuan Medical Health (02373) with a "Buy" rating and a target price of HKD 43.7, highlighting the company's dual-driven growth strategy of "internal growth + external expansion" [1] Group 1: Business Model - Meili Tianyuan adopts a "Double Beauty + Double Health" collaborative business model, creating a comprehensive health ecosystem that includes brands like Meili Tianyuan, Nairui'er, Xiuker, and Yanyuan, covering a full lifecycle of services from lifestyle beauty to high-end non-surgical medical aesthetics and health management [2] Group 2: Growth Strategy - The company enhances operational and integration capabilities through a dual-driven approach. Internally, it utilizes 38 self-developed systems for refined operations, maintaining a customer repurchase rate above 80% and customer acquisition costs below 2%. Externally, it leverages strong cash flow for strategic acquisitions like Nairui'er and Siyuanli, significantly increasing membership and net profit margins [3] Group 3: Industry Trends - Meili Tianyuan is positioned to lead the transformation of the beauty industry, capitalizing on trends of branding, chain development, and digitalization. Its multi-brand strategy and extensive store network allow it to strengthen its presence in high-tier cities while expanding customer value through the "Double Beauty + Double Health" ecosystem [4] Group 4: Financial Performance - In the first half of 2025, the company reported strong performance with direct store traffic reaching 920,000, a year-on-year increase of 47.8%. Active members grew to 120,000, up 46.5% year-on-year. Total revenue reached RMB 1,459 million, a 28.2% increase, with adjusted net profit at RMB 191 million and an adjusted net profit margin of 13.1%, showcasing robust profitability under macroeconomic pressures [5] Group 5: Valuation - The company has significant growth potential driven by both internal growth and acquisition capabilities. Using a discount rate of 10% and a perpetual growth rate of 3%, the estimated fair value is HKD 10.3 billion, with a target price of HKD 43.7, indicating a 65.4% upside from the previous closing price, corresponding to PE ratios of 29.8 and 24.5 for 2025 and 2026 respectively [6]

Group 1 - The company announced the acquisition of 100% equity in Siyuanli for 1.25 billion RMB (approximately 1.369 billion HKD), aiming to further industry consolidation [1] - Siyuanli, established in 1996, is the third-largest beauty service brand in China, with 182 stores as of June 2024, including 163 beauty stores and 19 medical beauty stores across 48 cities [1] - Post-acquisition, the company's total store count will exceed 700, enhancing market share and accelerating the "Double Beauty + Double Healthcare" strategic layout [1] Group 2 - The company increased its stake in Nairui to 90% after acquiring 70% equity for a total consideration of 350 million RMB, with Nairui being the second-largest traditional beauty service brand in China [2] - In July 2024, the company announced the inclusion of 75 remaining Nairui stores through franchising, adding a total of 150 new stores to its network [2] - Nairui's revenue reached 277 million RMB in the first half of 2025, with adjusted net profit margin improving from 6.5% before acquisition to 10.4% post-acquisition [2] Group 3 - The company held a strategic upgrade conference on November 19, announcing three major strategies: Super Brand, Super Chain, and Super Digitalization [3] - The Super Brand strategy focuses on integrating the top three brands in the industry, including Meili Tianyuan, Nairui, and Siyuanli, to strengthen brand advantages [3] - The company has invested over 200 million RMB in digitalization, achieving double-digit growth in new member acquisition and maintaining a member retention rate of 80% in the following year [3] Group 4 - The company maintains a buy rating, adjusting the 2025 adjusted earnings per share forecast from 1.34 RMB to 1.59 RMB, with new forecasts for 2026 and 2027 set at 2.05 RMB and 2.29 RMB, respectively [3] - The target price has been raised from 19.84 HKD to 37.13 HKD, indicating a potential upside of 41% [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation of performance relative to the market [4]. Core Insights - The company is focusing on a dual-driven strategy of organic growth and acquisitions, with a particular emphasis on three major strategic areas: Super Brand, Super Chain, and Super Digitalization [6]. - The acquisition of 100% of the shares of Siyanli for 1.25 billion RMB (approximately 1.369 billion HKD) is expected to enhance market share and accelerate the company's strategic layout [4]. - The company has increased its stake in Nairui to 90%, with significant improvements in operational efficiency post-acquisition, reflected in a rise in adjusted net profit margin from 6.5% to 10.4% [5]. Financial Data and Earnings Forecast - The company forecasts revenue growth from 2,145 million RMB in 2023 to 4,541 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 31.16% [8]. - Adjusted net profit is projected to increase from 241 million RMB in 2023 to 540 million RMB in 2027, with a notable growth rate of 53.18% in 2023 [8]. - The adjusted earnings per share (EPS) is expected to rise from 1.05 RMB in 2023 to 2.29 RMB in 2027, reflecting a strong upward trend in profitability [8].

（股 份 代 號：2373） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） 於股東特別大會舉行日期，已發行股份總數為235,795,568股股份，其中940,000股 股份為持有或寄存於香港中央結算有限公司成立及運作的中央結算及交收系統的庫 存股，且概無該等庫存股之投票權於股東特別大會上獲行使。根據上市規則第 17.05A條，本公司所採納的2022年股份激勵計劃的受託人就其持有的未歸屬激勵股 份（即6,185,568股股份）於股東特別大會上放棄投票。因此，賦予股東權利出席股東 特別大會並於會上就所提呈的決議案投票的股份總數為228,670,000股。 於2025年12月5日舉行的股東特別大會投票結果 董事會宣佈，該通告所載的決議案已於股東特別大會上以投票表決方式獲股東 ...

Core Viewpoint - The company, 美丽田园医疗健康 (02373.HK), demonstrates strong confidence in its future development through share purchases by its non-executive director, 李方雨, and the company's own share buybacks [1] Group 1: Shareholder Activity - Non-executive director 李方雨 has increased his shareholding by 52,000 shares as of December 3, 2025, and a total of 114,500 shares since December 1, 2025, indicating a strong belief in the company's future prospects [1] - The company has repurchased 74,500 shares on the same day, with a total transaction amount of approximately 1.9429 million HKD, at an average price of about 26.08 HKD per share [1] - From October 15, 2025, to the present, the company has repurchased a total of 849,500 shares for approximately 24.636 million HKD [1]

Core Viewpoint - The company, 美丽田园医疗健康 (02373), demonstrates confidence in its future prospects through share buybacks and insider purchases, indicating a belief that current share prices do not reflect intrinsic value [1] Group 1: Insider Transactions - Non-executive director Li Fangyu has increased her stake in the company by 52,000 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - From December 1 to the announcement date, Li Fangyu has acquired a total of 114,500 shares, reflecting her strong belief in the company's future development [1] Group 2: Share Buyback Activity - On December 3, 2025, the company repurchased 74,500 shares at a total cost of approximately HKD 1.94285 million, with an average transaction price of about HKD 26.08 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 849,500 shares for approximately HKD 24.636 million [1] Group 3: Management's Perspective - The board believes that the current share price does not reflect the intrinsic value and actual business prospects of the company [1] - The share buyback is seen as a demonstration of management's confidence in the long-term value of the company, which is expected to enhance market value and shareholder returns [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) announced that non-executive director Li Fangyu has increased her equity in the company by 52,000 shares, representing approximately 0.02% of the total issued shares as of the announcement date, reflecting her strong confidence in the company's future development [1] Group 1: Shareholder Actions - Li Fangyu has acquired a total of 114,500 shares from December 1 to the announcement date, indicating her commitment to the company's growth [1] - The company repurchased 74,500 shares on December 3, with a total transaction amount of approximately HKD 1.94285 million, at an average price of HKD 26.08 per share [1] - From October 15 to the announcement date, the company has repurchased a total of 849,500 shares for approximately HKD 24.636 million [1] Group 2: Management Perspective - The board believes that the current share price does not reflect the intrinsic value and actual business prospects of the company [1] - The board is confident that the share repurchase demonstrates management's commitment to the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]